Literature DB >> 19573038

Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines.

Rüdiger Hardeland1, Dun-Xian Tan2, Russel J Reiter2.   

Abstract

Kynuramines represent their own class of biogenic amines. They are formed either by decarboxylation of kynurenines or pyrrole ring cleavage of indoleamines. N(2)-formylated compounds formed in this last reaction can be deformylated either enzymatically by arylamine formamidases or hemoperoxidases, or photochemically. The earlier literature mainly focussed on cardiovascular effects of kynuramine, 5-hydroxykynuramine and their N(1),N(1)-dimethylated analogs, including indirect effects via release of catecholamines or acetylcholine and interference with serotonin receptors. After the discovery of N(1)-acetyl-N(2)-formyl-5-methoxykynuramine (AFMK) and N(1)-acetyl-5-methoxykynuramine (AMK) as major brain metabolites of melatonin, these compounds became of particular interest. They were shown to be produced enzymatically, pseudoenzymatically, by various free radical-mediated and via photochemical processes. In recent years, AFMK and AMK were shown to scavenge reactive oxygen and nitrogen species, thereby forming several newly discovered 3-indolinone, cinnolinone and quinazoline compounds, and to protect tissues from damage by reactive intermediates in various models. AMK is of special interest due to its properties as a potent cyclooxygenase inhibitor, NO scavenger forming a stable nitrosation product, inhibitor and/or downregulator of neuronal and inducible NO synthases, and a mitochondrial metabolism modulator. AMK easily interacts with aromates, forms adducts with tyrosyl and tryptophanyl residues, and may modify proteins.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19573038     DOI: 10.1111/j.1600-079X.2009.00701.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  91 in total

1.  Melatonin in aging and disease -multiple consequences of reduced secretion, options and limits of treatment.

Authors:  Rüdiger Hardeland
Journal:  Aging Dis       Date:  2011-02-10       Impact factor: 6.745

2.  Therapeutic potential of melatonin and its analogs in Parkinson's disease: focus on sleep and neuroprotection.

Authors:  Venkatramanujam Srinivasan; Daniel P Cardinali; Uddanapalli S Srinivasan; Charanjit Kaur; Gregory M Brown; D Warren Spence; Rüdiger Hardeland; Seithikurippu R Pandi-Perumal
Journal:  Ther Adv Neurol Disord       Date:  2011-09       Impact factor: 6.570

Review 3.  Mitochondrial DNA and inflammatory diseases.

Authors:  Germaine Escames; Luis Carlos López; José Antonio García; Laura García-Corzo; Francisco Ortiz; Darío Acuña-Castroviejo
Journal:  Hum Genet       Date:  2011-07-07       Impact factor: 4.132

4.  Metabolism of melatonin and biological activity of intermediates of melatoninergic pathway in human skin cells.

Authors:  Tae-Kang Kim; Konrad Kleszczynski; Zorica Janjetovic; Trevor Sweatman; Zongtao Lin; Wei Li; Russel J Reiter; Tobias W Fischer; Andrzej T Slominski
Journal:  FASEB J       Date:  2013-04-25       Impact factor: 5.191

5.  Secretion of melatonin and 6-sulfatoxymelatonin urinary excretion in functional dyspepsia.

Authors:  Cezary Chojnacki; Tomasz Poplawski; Grażyna Klupinska; Janusz Blasiak; Jan Chojnacki; Russel J Reiter
Journal:  World J Gastroenterol       Date:  2011-06-07       Impact factor: 5.742

Review 6.  Melatonin: A Cutaneous Perspective on its Production, Metabolism, and Functions.

Authors:  Andrzej T Slominski; Ruediger Hardeland; Michal A Zmijewski; Radomir M Slominski; Russel J Reiter; Ralf Paus
Journal:  J Invest Dermatol       Date:  2018-02-07       Impact factor: 8.551

7.  Melatonin protects lung mitochondria from aging.

Authors:  Darío Acuña-Castroviejo; Miguel Carretero; Carolina Doerrier; Luis C López; Laura García-Corzo; Jesús A Tresguerres; Germaine Escames
Journal:  Age (Dordr)       Date:  2011-05-26

8.  Impaired mitochondrial complex III and melatonin responsive reactive oxygen species generation in kidney mitochondria of db/db mice.

Authors:  Hua Zhang; Hong-Mei Zhang; Li-Ping Wu; Dun-Xian Tan; Amrita Kamat; Yun-Qing Li; Michael S Katz; Hanna E Abboud; Russel J Reiter; Bin-Xian Zhang
Journal:  J Pineal Res       Date:  2011-05-27       Impact factor: 13.007

9.  A protective effect of melatonin on intestinal permeability is induced by diclofenac via regulation of mitochondrial function in mice.

Authors:  Qiao Mei; Lei Diao; Jian-ming Xu; Xiao-chang Liu; Juan Jin
Journal:  Acta Pharmacol Sin       Date:  2011-03-28       Impact factor: 6.150

10.  The anti-inflammatory effect of melatonin on methamphetamine-induced proinflammatory mediators in human neuroblastoma dopamine SH-SY5Y cell lines.

Authors:  Kannika Permpoonputtana; Piyarat Govitrapong
Journal:  Neurotox Res       Date:  2012-08-18       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.